MX2023002256A - Inhibidores de sarm1. - Google Patents
Inhibidores de sarm1.Info
- Publication number
- MX2023002256A MX2023002256A MX2023002256A MX2023002256A MX2023002256A MX 2023002256 A MX2023002256 A MX 2023002256A MX 2023002256 A MX2023002256 A MX 2023002256A MX 2023002256 A MX2023002256 A MX 2023002256A MX 2023002256 A MX2023002256 A MX 2023002256A
- Authority
- MX
- Mexico
- Prior art keywords
- sarm1
- inhibitors
- treating
- present disclosure
- disclosure provides
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción proporciona compuestos y métodos útiles para inhibir SARM1 y/o tratar y/o prevenir la degeneración axonal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063069408P | 2020-08-24 | 2020-08-24 | |
US202163142398P | 2021-01-27 | 2021-01-27 | |
PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002256A true MX2023002256A (es) | 2023-03-17 |
Family
ID=77775005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002256A MX2023002256A (es) | 2020-08-24 | 2021-08-23 | Inhibidores de sarm1. |
Country Status (17)
Country | Link |
---|---|
US (1) | US12043613B2 (es) |
EP (1) | EP4200293A1 (es) |
JP (2) | JP7349046B2 (es) |
KR (1) | KR20230057396A (es) |
AU (2) | AU2021333558C1 (es) |
BR (1) | BR112023002575A2 (es) |
CA (1) | CA3189181A1 (es) |
CL (1) | CL2023000525A1 (es) |
CO (1) | CO2023001975A2 (es) |
CR (1) | CR20230113A (es) |
DO (1) | DOP2023000038A (es) |
EC (1) | ECSP23012981A (es) |
IL (1) | IL300586A (es) |
MX (1) | MX2023002256A (es) |
PE (1) | PE20230737A1 (es) |
TW (2) | TW202334117A (es) |
WO (1) | WO2022046606A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230339913A1 (en) * | 2020-08-04 | 2023-10-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
WO2022060812A1 (en) | 2020-09-16 | 2022-03-24 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
EP4376840A1 (en) | 2021-07-28 | 2024-06-05 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
TW202412817A (zh) * | 2022-07-21 | 2024-04-01 | 美商艾米利克斯製藥公司 | 寡核苷酸組合物及其方法 |
WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
WO2024158775A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンa3受容体拮抗剤およびチアゾール化合物 |
US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
WO2004041813A1 (en) | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
WO2006065946A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
CN101472921B (zh) | 2006-06-28 | 2012-10-10 | Aska制药株式会社 | 吡啶基异*唑衍生物 |
AU2007299261A1 (en) | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
PA8809001A1 (es) | 2007-12-20 | 2009-07-23 | Novartis Ag | Compuestos organicos |
JP2011506563A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | ビスチアゾール誘導体、その製造方法および医薬品としてのその使用 |
TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
WO2010093849A2 (en) | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
WO2014070978A1 (en) | 2012-11-03 | 2014-05-08 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
WO2014099694A1 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
US20160304466A1 (en) | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
EP4091622A1 (en) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
US11253503B2 (en) | 2016-09-24 | 2022-02-22 | Washington University | Inhibitors of SARM1 NADase activity and uses thereof |
UY37512A (es) | 2016-12-09 | 2019-04-30 | Vertex Pharma | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga |
EP3558986A1 (de) * | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
BR112019012567A2 (pt) | 2016-12-22 | 2019-11-26 | Bayer Ag | azolilpirrolonas e azolil-hidantoínas substituídas e sais das mesmas e uso das mesmas como substâncias ativas herbicidas |
CA3085460A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
EP3801500A4 (en) | 2018-06-07 | 2022-03-02 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
WO2019236890A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
EP3801499B1 (en) | 2018-06-07 | 2024-02-28 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
EP3919055A4 (en) | 2019-01-30 | 2022-11-09 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
US20220242859A1 (en) | 2019-06-06 | 2022-08-04 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
CN113966217A (zh) | 2019-06-14 | 2022-01-21 | 达萨玛治疗公司 | Sarm1抑制剂 |
US20220289691A1 (en) | 2019-07-22 | 2022-09-15 | Bayer Aktiengesellschaft | 5-amino-substituted pyrazoles and triazoles as pest control agents |
CA3150878A1 (en) | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
CN114845709A (zh) | 2019-11-05 | 2022-08-02 | 德米拉公司 | 用于治疗炎性病症的mrgprx2拮抗剂 |
EP4087838A1 (en) | 2020-01-07 | 2022-11-16 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
EP4132928A1 (en) | 2020-04-09 | 2023-02-15 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of sarm1 |
US20230286978A1 (en) | 2020-04-09 | 2023-09-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
US20230339913A1 (en) | 2020-08-04 | 2023-10-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Search and Examination
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en active Application Filing
-
2023
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP2024016014A/ja active Pending
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021333558B2 (en) | 2024-02-22 |
JP2024016014A (ja) | 2024-02-06 |
BR112023002575A2 (pt) | 2023-03-07 |
CA3189181A1 (en) | 2022-03-03 |
US20220056013A1 (en) | 2022-02-24 |
JP7349046B2 (ja) | 2023-09-21 |
ECSP23012981A (es) | 2023-03-31 |
JP2023535236A (ja) | 2023-08-16 |
WO2022046606A1 (en) | 2022-03-03 |
EP4200293A1 (en) | 2023-06-28 |
PE20230737A1 (es) | 2023-05-03 |
AU2021333558A1 (en) | 2023-03-02 |
CL2023000525A1 (es) | 2023-09-15 |
US12043613B2 (en) | 2024-07-23 |
CO2023001975A2 (es) | 2023-03-07 |
AU2021333558C1 (en) | 2024-06-20 |
KR20230057396A (ko) | 2023-04-28 |
TW202214597A (zh) | 2022-04-16 |
IL300586A (en) | 2023-04-01 |
DOP2023000038A (es) | 2023-03-15 |
CR20230113A (es) | 2023-04-14 |
TWI786777B (zh) | 2022-12-11 |
AU2024203373A1 (en) | 2024-06-13 |
TW202334117A (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220167A1 (ar) | مثبطات sarm1 | |
MX2023002256A (es) | Inhibidores de sarm1. | |
WO2020252229A3 (en) | Inhibitors of sarm1 | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
AU2018301696A8 (en) | Heterocyclic inhibitors of ATR kinase | |
WO2020247701A3 (en) | Inhibitors of sarm1 | |
MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
MX2022001004A (es) | Inhibidores de enzimas. | |
CR20230325A (es) | Compuestos de indazol como inhibidores de cinasas | |
CR20230362A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
MX2023011608A (es) | Metodos para inhibir ras. | |
MX2020009147A (es) | Moduladores de la expresion de irf4. | |
MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
MX2023013912A (es) | Metodos para inhibir ras. | |
MX2022000811A (es) | Inhibidores de enzimas. | |
MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
AU2020378127A8 (en) | Compounds as CD73 inhibitors | |
MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
EP2456456A4 (en) | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE OR NEURONAL DEGENERATION | |
MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). | |
MX2021010152A (es) | Moduladores de la expresion de malat1. | |
MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. |